Rational Engineering of Islet Tolerance via Biomaterial-Mediated Immune Modulation
- 15 January 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 212 (2) , 216-224
Abstract
Type 1 diabetes (T1D) onset is characterized by an autoimmune attack on β islet cells within the pancreas, preventing the insulin secretion required to maintain glucose homeostasis. Targeted modulation of key immunoregulatory cell populations is a promising strategy to restore tolerance to β cells. This strategy can be used to prevent T1D onset or reverse T1D with transplanted islets. To this end, drug delivery systems can be employed to transport immunomodulatory cargo to specific cell populations that inhibit autoreactive T cell–mediated destruction of the β cell mass. The rational engineering of biomaterials into nanoscale and microscale drug carriers can facilitate targeted interactions with immune cells. The physicochemical properties of the biomaterial, the delivered immunomodulatory agent, and the target cell populations are critical variables in the design of these delivery systems. In this review, we discuss recent biomaterials-based drug delivery approaches to induce islet tolerance and the need to consider both immune and metabolic markers of disease progression.Keywords
Funding Information
- HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (R21AI159795)
- JDRF (3-SRA-2023-1389-S-B)
This publication has 87 references indexed in Scilit:
- Application of IgG-Derived Natural Treg Epitopes (IgG Tregitopes) to Antigen-Specific Tolerance Induction in a Murine Model of Type 1 DiabetesJournal of Diabetes Research, 2013
- Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patientsJournal of Experimental Medicine, 2012
- In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particlesProceedings of the National Academy of Sciences, 2011
- Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?Immunity, 2010
- Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetesNature Immunology, 2010
- The mechanisms of alloxan- and streptozotocin-induced diabetesDiabetologia, 2007
- Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody1Transplantation, 2003
- Pancreatic Lymph Nodes Are Required for Priming of β Cell Reactive T Cells in NOD MiceJournal of Experimental Medicine, 2002
- Unexplained Deaths of Type 1 Diabetic PatientsDiabetic Medicine, 1991
- Diabetogenic action of streptozotocin: relationship of dose to metabolic responseJournal of Clinical Investigation, 1969